<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04286529</url>
  </required_header>
  <id_info>
    <org_study_id>19-010890</org_study_id>
    <nct_id>NCT04286529</nct_id>
  </id_info>
  <brief_title>Effect of 1,25-dihydroxyvitamin D3, Treatment on Insulin Secretion and Muscle Strength in Pre-diabetic Persons</brief_title>
  <official_title>Effect of 1,25-dihydroxyvitamin D3, Treatment on Insulin Secretion and Muscle Strength in Pre-diabetic Persons</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the effects of 1,25(OH)2D3 on insulin secretion by the
      pancreas and glucose utilization by skeletal muscle as well as to determine the effects of
      1,25(OH)2D3 on muscle strength in pre-diabetic persons
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose Tolerance Test</measure>
    <time_frame>8 weeks</time_frame>
    <description>After an overnight fast, participants will report to the Clinical Research and Trials Unit. Participants will ingest a drink containing 75g glucose. A blood draw will be obtained for measurement of glucose .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose Tolerance Test</measure>
    <time_frame>8 weeks</time_frame>
    <description>After an overnight fast, participants will report to the Clinical Research and Trials Unit. Participants will ingest a drink containing 75g glucose. A blood draw will be obtained for measurement of insulin .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose Tolerance Test</measure>
    <time_frame>8 weeks</time_frame>
    <description>After an overnight fast, participants will report to the Clinical Research and Trials Unit. Participants will ingest a drink containing 75g glucose. A blood draw will be obtained for measurement of C-peptide .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PROMIS 10 Questionnaire</measure>
    <time_frame>8 weeks</time_frame>
    <description>Brief 10 question multiple choice survey</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Pre-Diabetic</condition>
  <arm_group>
    <arm_group_label>Men-Calcitriol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcitriol (1,25(OH)2D3) 0.25mcg capsule daily for eight weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Premenopausal Women-Calcitriol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcitriol (1,25(OH)2D3) 0.25mcg capsule daily for eight weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Men-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.25mcg capsule daily for eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Premenopausal Women-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.25mcg capsule daily for eight weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol capsules</intervention_name>
    <description>0.25micrograms, taken daily for eight weeks, orally</description>
    <arm_group_label>Men-Calcitriol</arm_group_label>
    <arm_group_label>Premenopausal Women-Calcitriol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Placebo</intervention_name>
    <description>Placebo will be created to mimic the appearance of the study drug</description>
    <arm_group_label>Men-Placebo</arm_group_label>
    <arm_group_label>Premenopausal Women-Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) of &gt;24kg/m2

          -  Fasting serum glucose &lt;126 mg/dL

        Exclusion Criteria:

          -  BMI&lt;/=24 kg/m2

          -  Fasting serum glucose &gt;/=126 mg/dL

          -  Patient is taking Calcium or Vitamin D supplements and is unwilling to stop for 8
             weeks

          -  Serum Calcium &gt;10.2 mg/dL

          -  Serum inorganic phosphorous &gt;4.5mg/dL

          -  Pregnancy or breastfeeding

          -  Diagnosis of Diabetes Mellitus

          -  Diagnosis of Rheumatoid Arthritis

          -  Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)

          -  Renal in sufficiency/failure ( serum creatinine &gt;1.5 mg/dL men, &gt; 1.3 mg/dL women)

          -  Chronic active liver disease (bilirubin &gt;1.2 mg/dL, AST&gt;144IU/L, or ALT &gt;165 IU/L)

          -  History of chronic hepatitis

          -  Active coronary artery disease ( unstable angina, myocardial infarction, stroke and
             revascularization of coronary, peripheral or carotid artery within the last 3 months)

          -  Oral warfarin group medications or history of blood clotting disorders

          -  Platelet count &lt;100,000 per uL within the last 7 days

          -  Alcohol consumption greater than 2 glasses/day or other substance abuse

          -  Untreated or uncontrolled thyroid disorders (outside a TSH range of 0.5 to 10mIU/L)

          -  Debilitating chronic disease (at the discretion of the investigators)

          -  The presence of infections, highly communicable diseases ( AIDS, active tuberculosis,
             venereal disease, hepatitis)

          -  Any malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Menopausal status is of interest to the study.</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajiv Kumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine M Huyber, CCRP</last_name>
    <phone>507-266-0984</phone>
    <email>huyber.christine@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rajiv Kumar, MD</last_name>
    <phone>507-284-0020</phone>
    <email>kumar.rajiv@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Christine M Huyber</last_name>
      <phone>507-266-0984</phone>
      <email>huyber.christine@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 25, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Rajiv Kumar, M.D.</investigator_full_name>
    <investigator_title>Ruth and Vernon Taylor Professor, Distinguished Investigator Department of Medicine, Biochemistry and Molecular Biology</investigator_title>
  </responsible_party>
  <keyword>Pre-menopausal women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

